GlassScriptPhysician profile
Norma I Solis
NPI 1427454537
$149,555.73
in general payments reported to CMS, 2019-2025
22 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $22K · 2023: $38K · 2024: $40K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Consulting Fee: $19K · Travel and Lodging: $9,129 · Food and Beverage: $7,663 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,021.50 |
| Consulting Fee | $19,217.25 |
| Travel and Lodging | $9,129.23 |
| Food and Beverage | $7,662.66 |
| Education | $212.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76,240.64 | 2021-2025 | |
| Janssen Biotech, INC. | $26,131.27 | 2021-2025 | Stelara, Tremfya |
| Pfizer INC. | $11,644.57 | 2022-2025 | |
| Lilly USA, LLC | $11,409.42 | 2021-2025 | Omvoh |
| Eli Lilly and Company | $9,589.08 | 2021-2024 | Omvoh |
| Genentech USA, INC. | $2,950.21 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,892.99 | 2021-2024 | |
| Evoke Pharma, INC. | $1,990.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,774.61 | 2021-2024 | Entyvio |
| Celltrion USA INC. | $1,515.00 | 2024-2025 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $971.38 | 2023 | Dupixent |
| Celgene Corporation | $820.66 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $503.41 | 2025 | |
| Phathom Pharmaceuticals, INC. | $371.54 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.91 | 2021-2025 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $138.56 | 2021 | |
| Madrigal Pharmaceuticals | $121.22 | 2024 | Resmetirom |
| Janssen Scientific Affairs, LLC | $104.98 | 2021-2024 | Tremfya, Stelara |
| Genzyme Corporation | $97.46 | 2022 | |
| Ardelyx, INC. | $25.56 | 2024 | Ibsrela |
| Sandoz INC. | $25.00 | 2024 | |
| Amgen INC. | $24.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.